The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

This week’s episode of The Top Line dives into the discussion, featuring Fierce Biotech’s Gabrielle Masson ... the keys to success for an effective IPO and what to expect from the market ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...

药物开发公司Maze Therapeutics周一（1月27日）表示，该公司在纽约首次公开募股（IPO）中目标估值高达7.281亿美元，预计将成为今年首家在美国上市的生物技术公司。

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.